Introduction: Recently, Li Yuchun revealed in the show that he was seriously ill and could not walk for a time.
1. Li Yuchun's recent situation
Li Yuchun, born on March 10, 1984 in Chengdu, Sichuan Province, is a Chinese pop singer, actress, and the lifelong image spokesperson of Corn Love Fund .
In 2005, Li Yuchun won the national championship of " Super Girl " and appeared on the cover of " Times Magazine " (Asian Edition) in the United States; in 2006, he released his first album " Queen and Dream ", with annual sales of 1.37 million copies ; In 2007, he released the album "My" and launched the first national tour, and then appeared in the United States "Times Magazine"; in 2008, he released the album " Youth China ", which won the MTV Asian Music Awards China's Most Popular Singer Award; released the album in 2009 "Li Yuchun" won the Best Asian Singer Award at the Asian Music Festival. In 2011,
released the album " can dance literary youth ", becoming the first mainland singer to win the National Best Female Singer Award in Hong Kong's Top Ten Chinese Golden Songs; in 2012, he released the album "If we don't go crazy, we will be old", which won the most in Asia by South Korea MAMA. Best Singer Award; released the album "Savage Growth" in 2016, with annual sales exceeding 6.56 million copies; released the album "Popular" in 2017, reaching the top of the top-selling list.
On October 12, 2022, Li Yuchun revealed in the "My Bronze Age" program that last year, when he was rehearsing the program, he suddenly felt very uncomfortable. After going to the hospital for examination, the doctor told her that she had "ankylosing spondylitis". Tell the host that this disease is almost incurable, it can only relieve the symptoms and prevent the disease from deepening.
Li Yuchun also created a song called "Five Viscera" with this as the background, using music to express his impatience after being sick and his desire for health.
Ankylosing spondylitis is a autoimmune disease , a disease with inflammation of the sacroiliac joints and spinal attachment points as the main symptom, is the fibrosis and ossification of the large joints of the limbs, as well as the annulus fibrosus of the intervertebral disc and its adjacent connective tissue, with Ankylosis is a chronic inflammatory disease characterized by lesions.
initially manifested as lumbosacral pain, stiffness, relief after activity, often misdiagnosed as lumbar muscle strain or lumbar disc herniation , if not treated in time, ankylosing spondylitis can worsen step by step, resulting in joint and spinal stiffness , movement disorders, or even fractures, compressed nerves, unable to straighten the waist, the whole person "folded".
In the entertainment industry, Jay Chou , Zhang Jiayi and Cai Shaofen also suffer from ankylosing spondylitis. It's called "immortal cancer". Ankylosing spondylitis can affect the hip and sacroiliac joints associated with walking, and pain in the hip may make walking difficult, requiring crutches or wheelchair mobility. Jay Chou is full of energy on stage, but since his middle school days, he has been plagued by this disease. Once he was playing basketball with his classmates. After exercising, he came home sweating profusely. After a while, he felt back pain. At first, I thought it was caused by excessive exercise, but I didn't expect that my waist became more and more painful, so I had to go to the hospital and finally diagnosed with ankylosing spondylitis.
Second, the research progress of therapeutic drugs
With the continuous updating of treatment methods, the treatment of ankylosing spondylitis has changed from the era of traditional drugs to the era of biological agents. Adalimumab is a commonly used TNF-α antagonist, z2The adalimumab biosimilar of Hualan Bio (002007) has entered the clinical phase III. Hualan Bio is a key high-tech enterprise engaged in the research and development and production of blood products. It is the first to pass the GMP certification of blood products. The blood products are rich in variety and complete in specifications. It has human albumin, intravenous human immunoglobulin, human immunity Globulin , human prothrombin complex , lyophilized human fibrin glue for surgery and other blood products under the brand of " Hualan ". Among them, the freeze-dried human fibrin glue for surgery is included in the national 863 project. In the first half of 2022, Hualan Bio achieved an operating income of 2.349 billion yuan, a year-on-year increase of 82.32%; a net profit attributable to the parent of 583 million yuan, a year-on-year increase of 27.49%; a non-net profit of 463 million yuan, a year-on-year increase of 16.86% . In the first half of 2022, Hualan Bio's blood products business achieved revenue of 1.281 billion yuan, a year-on-year increase of 0.71%; of which the main blood product product albumin revenue was 475 million yuan, a year-on-year increase of 0.45%, with a gross profit margin of 50.70%; , the gross profit margin was 51.95%. During the 13th Five-Year Plan period, the approval of plasma stations in the whole industry has become stricter. In the first half of 2022, Hualan Bio has approved 4 new plasma stations, which are respectively approved in Huangchuan County, Xinyang City, Yichuan County, Luoyang City, Xiayi County, Shangqiu City, and Zhoukou City. Each of Shangshui County has set up a plasma apheresis station . Hualan's dominant position in Henan and Chongqing has become increasingly prominent, and multiple new plasma stations have been approved, opening up space for the growth of plasma collection of blood products.
In the first half of 2022, Hualan's biological vaccine sector achieved revenue of 1.056 billion yuan, mainly due to the fact that the 2022 flu vaccines began to be issued and sold in batches in May (no batches were issued in the first half of 2021). Terminal seeding is catalyzed. Among them, a total of 64 batches of quadrivalent influenza vaccines have been approved and issued, 52 batches of adult formulations and 12 batches of children's formulations. It is expected that the influenza vaccines are expected to achieve recovery growth in the second half of the year.
Hualan Bio released a series of announcements such as the 2022 restricted stock incentive plan (draft) and the list of incentive objects granted for the first time: it is planned to grant 4 million restricted shares to the incentive objects, accounting for 1% of the total share capital, and the grant price is 24.42 yuan /share. The incentive objects granted for the first time are 28 people, covering all directors, executives and key employees of Hualan Bio; 3.4 million shares were granted for the first time, accounting for 85% of the total equity granted; 600,000 shares were reserved, accounting for 15%.
Hualan Biological Incentive Plan first grants the restricted stock performance appraisal year from 2022 to 2024. The performance appraisal indicator is mainly the net profit after deduction. Based on the net profit in 2021, the target growth rates of the performance appraisal in the next three years are respectively 20%, 40% and 80%. The total amortization cost of restricted stocks granted for the first time is 65.53 million yuan, and the amortization costs for 2022-2025 are 6.02 million yuan, 33.47 million yuan, 18.49 million yuan and 7.55 million yuan respectively. After nearly 20 years of development, Hualan Bio has a total market value of more than 30 billion yuan, and has more than 30 wholly-owned subsidiaries. The "Hualan" trademark has become a recognized brand in China's blood products industry. Hualan Biology regards product quality as the life of the enterprise, persistently develops and produces safe, efficient and reliable products, and uses high technology as a technical means to create more brilliant performance in the new century.
